StocksMedium•27 October 2026•
1 min read
Oruka Therapeutics Stock Rises on Positive Psoriasis Trial Results
Key Facts
1Oruka Therapeutics reported positive Phase 2b EVERLAST-B data for ORKA-001 in patients with moderate-to-severe psoriasis.
261% of patients at a 600 mg dose achieved complete skin clearance by week 16.
Oruka Therapeutics reported positive Phase 2b EVERLAST-B data for its drug candidate ORKA-001 in patients with moderate-to-severe psoriasis. Yahoo Finance reported that 61% of patients at a 600 mg dose achieved complete skin clearance by week 16 of the trial.
ORKA closed at $90.33 on October 26, 2026, with the stock reaching a day high of $93.42 and a low of $81.98. The positive clinical results support the company's objective for infrequent dosing schedules, increasing the drug's competitive potential within the psoriasis market.